ImmunoGenesis Secures $10.8 Million Grant for Innovative Cancer Treatment Development ImmunoGenesis has received a significant $10.8 million grant from CPRIT to advance the clinical evaluation of their new therapy, IMGS-001, targeting immune-excluded tumors.

ImmunoGenesis Secures $10.8 Million Grant for Innovative Cancer Treatment Development #USA #Houston #ImmunoGenesis #IMGS-001 #CPRIT

ImmunoGenesis Establishes Scientific Advisory Board to Enhance Cancer Immunotherapy Research ImmunoGenesis has formed a Scientific Advisory Board to guide the clinical development of its innovative therapies, focusing on overcoming immune resistance in cancer treatments.

ImmunoGenesis Establishes Scientific Advisory Board to Enhance Cancer Immunotherapy Research #United_States #Cancer_Research #Houston,_Texas #ImmunoGenesis #IMGS-001

ImmunoGenesis Unveils Promising Results for IMGS-001 at ASCO 2025 Meeting At the 2025 ASCO Annual Meeting, ImmunoGenesis will share groundbreaking updates on its clinical study for IMGS-001, a dual-specific antibody aimed at tackling immune-excluded tumors.

ImmunoGenesis Unveils Promising Results for IMGS-001 at ASCO 2025 Meeting #USA #Chicago #ASCO_2025 #ImmunoGenesis #IMGS-001

ImmunoGenesis to Showcase Innovations at 2025 NeauxCancer Conference in New Orleans ImmunoGenesis will participate in the 2025 NeauxCancer Conference, presenting groundbreaking insights on their innovative immunotherapies aimed at combating cancer.

ImmunoGenesis to Showcase Innovations at 2025 NeauxCancer Conference in New Orleans #United_States #New_Orleans #cancer_therapies #ImmunoGenesis #NeauxCancer

ImmunoGenesis Begins Innovative Clinical Trial for Advanced Cancers Combining IMGS-101 with Balstilimab and Zalifrelimab ImmunoGenesis has initiated a clinical trial investigating IMGS-101 alongside Balstilimab and Zalifrelimab for challenging cancers, including advanced prostate and pancreatic tumors.

ImmunoGenesis Begins Innovative Clinical Trial for Advanced Cancers Combining IMGS-101 with Balstilimab and Zalifrelimab #USA #Houston #ImmunoGenesis #IMGS-101 #Balstilimab